Compteur de chargement des CP & publications

>
Titrenb de chargement
Transgene Announces Upcoming Investor Meetings1311
Transgene annonce ses prochaines rencontres avec les investisseurs1288
All of Transgene's preclinical and clinical assets progressed in line with expectations in Q1 20221480
Progression de tous les produits précliniques et cliniques de Transgene au premier trimestre 20222438
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination1208
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination1208
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients1230
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients1230
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG40505884
Transgene présente de nouvelles données préliminaires de Phase I confirmant le potentiel de TG4050 au congrès de l'AACR 20224246
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients3561
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF3561
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF3561
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients3561
Availability of Transgene's 2021 Universal Registration Document4495
Mise à disposition du document d'enregistrement universel 2021 de Transgene4143
Availability of Preparatory Documents for the Combined General Meeting of May 25, 20224323
Mise à disposition des documents préparatoires à l'Assemblée générale du 25 mai 20224059
Transgene's Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman6499
Le conseil d'administration de Transgene renforce sa gouvernance et propose la nomination du Dr Alessandro Riva en qualité de Président Indépendant4090
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 202217404
Transgene confirme le potentiel de ses deux plateformes innovantes et attend des résultats cliniques significatifs en 20225291
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 20228752
Transgene et BioInvent présenteront un poster à l'AACR 2022 sur BT-001, un virus oncolytique innovant5242
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 20227011
Transgene présentera des nouvelles données préliminaires positives des Phases I avec TG4050 à l'AACR 20225467
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment4727
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment4727
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors4727
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors4727
Éthique et conformité4727
Corporate governance4727
Ethics & compliance4727
Transgene appoints Steven Bloom as Chief Business Officer9603
Transgene annonce la nomination de Steven Bloom au poste de Directeur du Business Development5269
Ethics and compliance4727
Éthique & conformité4727
Custom Styles4729
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors4733
Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors4733
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade7237
Transgene et BioInvent publient dans le JITC des données de preuve de concept préclinique du virus oncolytique BT-0016909
4733
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors13533
Transgene et PersonGen annoncent une collaboration pour l'évaluation d'une nouvelle combinaison thérapeutique contre les tumeurs solides11307
Transgene announces Financial Calendar for 20225490
Transgene présente son calendrier de communication financière pour 20225852
Biomed Event - Paris7945
Biomed Event - Paris7945
Biotech Showcase Investor Conference – Digital- January 17 to 19, 20227945
Biotech Showcase Investor Conference – Virtuel - 17 au 19 janvier 20227945
Biotech Showcase Investor Conference, in conjunction with the J.P. Morgan Healthcare conference - Digital - January 10 to 12, 20227945
Biotech Showcase Investor Conference, en parallèle de la conférence annuelle J. P. Morgan - Virtu - 10 au 12 janvier 20227945
25th ODDO BHF Digital Forum - Digital - January 6, 7, 10 and 11, 20227945
11ème édition du LifeSci Advisors Corporate Access Event - Virtuel - 5 au 7 janvier 20227945
11th Annual LifeSci Advisors Corporate Access Event - Digital - January 5 to 7, 20227945
ODDO BHF Digital Forum - Virtuel - 6, 7, 10 et 11 janvier 20227945
Transgene announces investor Meeting for January 20228546
Transgene annonce ses rencontres avec les investisseurs en janvier 202210002
License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO™ Platform7945
Levée d’Option de Licence par AstraZeneca pour un Virus Oncolytique issu de la Plateforme Invir.IO™7945
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform31869
Transgene annonce une levée d’option de licence par AstraZeneca pour un virus oncolytique issu de sa plateforme Invir.IO™11353
TG4050, First positive clinical data from Phase I clinical trials7945
TG4050, Premiers résultats positifs des essais de Phase I (en français)7945
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine19620
Transgene et NEC annoncent des premiers résultats positifs des essais de Phase I de TG4050, un vaccin thérapeutique individualisé innovant contre le cancer10085
annonceHome7945
annonceHomeUS7945
TG40507945
Icon7945
TG40507945
annonce substitut7945
annonce7945
Careers7945
Annual General Meeting7945
événements et presentations7945
Analysts7945
General7945
Key figures7945
Financial reports7945
Information boursière7945
Financial information7945
Regulated information7945
Publications7945
RH(en)7945
Icon7945
Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 20218377
Transgene reports business update and Q3 2021 financial position7945
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 20218144
Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 20218567
Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 20218540
Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 20218188
annonce substitut7945
annonce7945
annonce7945
TG40507945
Nous rejoindre7945
esmo7945
esmo20217945
bg37945
bg27945
bg17945
Statistiques7945
RH7945
produits : BT-0017945
produits : TG60027945
produits : TG40017945
produits : TG40507945
Publications7945
techno invirio7945
techno myvac7945
techno Oncolytic viruses7945
techno Therapeutic Vaccines7945
FAQ7945
7945
produits : 5 OVs teaser7945
produits : OVs teaser7945
produits : BT-001 teaser7945
produits : TG6002 teaser7945
produits : TG4001 teaser7945
produits : TG4050 teaser7945
pipeline7945
CORPORATE GOVERNANCE7945
Dr. Laurence ZITVOGEL7945
Sandrine Flory TSGH7945
Maya SAID7945
Alain MÉRIEUX7945
Marie LANDEL7945
Benoît HABERT7945
Dr. Jean-Pierre BIZZARI7945
Antoine BÉRET7945
Jean-Luc BÉLINGARD7945
conseil7945
Philippe ARCHINARD7945
Gaëlle STADTLER7945
John FELITTI7945
Steven Bloom7945
Jean-Philippe Del7945
Maud BRANDELY7945
Christophe ANCEL7945
Eric QUÉMÉNEUR7945
Hedi Ben Brahim7945
Management committee7945
Home news plugin7945
innovation box7945
TG4001 box7945
myvac-box7945
invirio-box7945
videos7945